mTORC2

/ DISEASE & DISORDERS, SCIENCE / By
  1. Regulation of mTORC2 signaling
  2. New insights into mTOR signaling: mTORC2 and beyond
  3. mTORC2 in the center of cancer metabolic reprogramming
  4. Activation of mTORC2 by association with the ribosome
  5. Localization of mTORC2 activity inside cells
  6. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
  7. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
  8. mTORC2 promotes tumorigenesis via lipid synthesis
  9. mTORC1 and mTORC2 in cancer and the tumor microenvironment
  10. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation
  11. Regulation and metabolic functions of mTORC1 and mTORC2
  12. Architecture of the human mTORC2 core complex
  13. A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation
  14. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
  15. Endoplasmic reticulum is a main localization site of mTORC2
  16. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
  17. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size
  18. AMPK directly activates mTORC2 to promote cell survival during acute energetic stress
  19. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship
  20. Growth factor-dependent and-independent activation of mTORC2
  21. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
  22. Oncogenic EGFR signaling activates an mTORC2–NF-κB pathway that promotes chemotherapy resistance
  23. mTORC2 controls actin polymerization required for consolidation of long-term memory
  24. The functional proximal proteome of oncogenic Ras includes mTORC2
  25. Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2
  26. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c
  27. MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
  28. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin
  29. mTORC2 caught in a SINful Akt
  30. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014
  31. PRICKLE1 contributes to cancer cell dissemination through its interaction with mTORC2
  32. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2
  33. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3, 4, 5-trisphosphate
  34. HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease
  35. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor
  36. mTORC2 signaling drives the development and progression of pancreatic cancer
  37. Towards specific inhibition of mTORC2
  38. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects
  39. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation
  40. … nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and …
  41. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
  42. mTORC2 is required for proliferation and survival of TSC2-null cells
  43. PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12
  44. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
  45. A critical role for the mTORC2 pathway in lung fibrosis
  46. XPLN is an endogenous inhibitor of mTORC2
  47. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2
  48. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation
  49. Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency
  50. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
  51. mTORC1‐and mTORC2‐interacting proteins keep their multifunctional partners focused
  52. mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif
  53. mTORC2 regulates cardiac response to stress by inhibiting MST1
  54. Disruption of the scaffolding function of mLST8 selectively inhibits mTORC2 assembly and function and suppresses mTORC2-dependent tumor growth in vivo
  55. Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt
  56. mTORC2 signaling promotes skeletal growth and bone formation in mice
  57. mTORC2 regulates neutrophil chemotaxis in a cAMP-and RhoA-dependent fashion
  58. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway
  59. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function
  60. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
  61. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex
  62. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways
  63. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression
  64. Hypothalamic mTORC2 is essential for metabolic health and longevity
  65. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2
  66. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1
  67. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer
  68. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling
  69. Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival
  70. mTORC2: The other mTOR in autophagy regulation
  71. Hepatic Sirt1 deficiency in mice impairs mTORC2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance
  72. Autophagy drives fibroblast senescence through mTORC2 regulation
  73. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide
  74. Lysosomal mTORC2/PHLPP1/Akt regulate chaperone-mediated autophagy
  75. Unraveling the regulation of mTORC2 using logical modeling
  76. mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors
  77. mTORC2 signaling: A path for pancreatic β cell’s growth and function
  78. Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology
  79. The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex
  80. Pharmacological inhibition of mTORC2 reduces migration and metastasis in melanoma
  81. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts
  82. Pathogenic role of mTORC1 and mTORC2 in pulmonary hypertension
  83. RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity
  84. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis
  85. mTORC2 regulates mechanically induced cytoskeletal reorganization and lineage selection in marrow‐derived mesenchymal stem cells
  86. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways
  87. Mitochondrial perturbations couple mTORC2 to autophagy in C. elegans
  88. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling
  89. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
  90. The mTORC2‐Akt1 cascade is crucial for c‐Myc to promote hepatocarcinogenesis in mice and humans
  91. mTORC1 and mTORC2 differentially promote natural killer cell development
  92. mTORC2 targets AGC kinases through Sin1-dependent recruitment
  93. Hsp70 associates with Rictor and is required for mTORC2 formation and activity
  94. mTORC2 mediates CXCL12-induced angiogenesis
  95. Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation
  96. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation
  97. Rictor/mTORC2 is essential for maintaining a balance between β-cell proliferation and cell size
  98. Significance of filamin A in mTORC2 function in glioblastoma
  99. Poxviruses evade cytosolic sensing through disruption of an mTORC1-mTORC2 regulatory circuit
  100. mTORC2 controls cancer cell survival by modulating gluconeogenesis
  101. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary
  102. Ras, PI3K and mTORC2–three’s a crowd?
  103. mTORC2 critically regulates renal potassium handling
  104. Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function
  105. mTORC2 is required for rit-mediated oxidative stress resistance
  106. ER stress inhibits mTORC2 and Akt signaling through GSK-3β–mediated phosphorylation of Rictor
  107. AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules
  108. mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis
  109. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism
  110. Lysosome positioning influences mTORC2 and AKT signaling
  111. Calorie-restriction-induced insulin sensitivity is mediated by adipose mTORC2 and not required for lifespan extension
  112. mTORC2 is a tyrosine kinase
  113. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways
  114. Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis
  115. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
  116. Combating herpesvirus encephalitis by potentiating a TLR3–mTORC2 axis
  117. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting
  118. mTORC2 regulates PGE2-mediated endothelial cell survival and migration
  119. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors
  120. Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers
  121. Novel inhibitors of mTORC1 and mTORC2.
  122. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses
  123. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells
  124. In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons
  125. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma
  126. mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
  127. TGFB-INHB/activin signaling regulates age-dependent autophagy and cardiac health through inhibition of mTORC2
  128. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors
  129. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
  130. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications
  131. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition
  132. mTORC2 signaling selectively regulates the generation and function of tissue-resident peritoneal macrophages
  133. PI3K/Akt promotes feedforward mTORC2 activation through IKKα
  134. Targeted inhibition of rictor/mTORC2 in cancer treatment: a new era after rapamycin
  135. mTORC1 is necessary but mTORC2 and GSK3β are inhibitory for AKT3-induced axon regeneration in the central nervous system
  136. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis
  137. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes
  138. Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling
  139. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
  140. Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication
  141. A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2
  142. Regulation of the epithelial Na+ channel by the mTORC2/SGK1 pathway
  143. Membrane tension acts through PLD2 and mTORC2 to limit actin network assembly during neutrophil migration
  144. Autophagy fosters myofibroblast differentiation through mTORC2 activation and downstream upregulation of CTGF
  145. mTORC2 signaling regulates Nox4-induced podocyte depletion in diabetes
  146. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models
  147. mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis
  148. mTORC2 responds to glutamine catabolite levels to modulate the hexosamine biosynthesis enzyme GFAT1
  149. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
  150. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
  151. mTORC2 and metabolic reprogramming in GBM: at the interface of genetics and environment
  152. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
  153. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways
  154. mTORC2 assembly is regulated by USP9X-mediated deubiquitination of RICTOR
  155. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
  156. PI3K–mTORC2 but not PI3K–mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma
  157. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2
  158. mTORC2 protein-mediated protein kinase B (Akt) serine 473 phosphorylation is not required for Akt1 activity in human platelets
  159. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells
  160. DNMT3b modulates melanoma growth by controlling levels of mTORC2 component RICTOR
  161. A microRNA program in the C. elegans hypodermis couples to intestinal mTORC2/PQM-1 signaling to modulate fat transport
  162. PI3K/mTORC2 regulates TGF-β/Activin signalling by modulating Smad2/3 activity via linker phosphorylation
  163. The SIN1-PH domain connects mTORC2 to PI3K
  164. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
  165. Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease
  166. Phosphorylated Rho–GDP directly activates mTORC2 kinase towards AKT through dimerization with Ras–GTP to regulate cell migration
  167. mTORC2 and AMPK differentially regulate muscle triglyceride content via Perilipin 3
  168. Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation
  169. Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice
  170. Genetic inactivation of mTORC1 or mTORC2 in neurons reveals distinct functions in glutamatergic synaptic transmission
  171. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014
  172. Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2
  173. A positive feedback loop between Sestrin2 and mTORC2 is required for the survival of glutamine-depleted lung cancer cells
  174. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
  175. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT
  176. Yap/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis
  177. Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity
  178. Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling
  179. mTORC2-mediated direct phosphorylation regulates YAP activity promoting glioblastoma growth and invasive characteristics
  180. The lipid handling capacity of subcutaneous fat is programmed by mTORC2 during development
  181. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
  182. Ovariectomy uncouples lifespan from metabolic health and reveals a sex-hormone-dependent role of hepatic mTORC2 in aging
  183. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
  184. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure
  185. mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity
  186. Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function
  187. FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer
  188. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
  189. Non-canonical mTORC2 signaling regulates brown adipocyte lipid catabolism through SIRT6-FoxO1
  190. Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling
  191. mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation
  192. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release
  193. AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin
  194. mTORC2 is the hydrophobic motif kinase for SGK1
  195. mTORC1 and mTORC2 expression in inner retinal neurons and glial cells
  196. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling
  197. CYP3A5 functions as a tumor suppressor in hepatocellular carcinoma by regulating mTORC2/Akt signaling
  198. Mechanically activated Fyn utilizes mTORC2 to regulate RhoA and adipogenesis in mesenchymal stem cells
  199. Association of mSin1 with mTORC2 Ras and Akt reveals a crucial domain on mSin1 involved in Akt phosphorylation
  200. Repression of human papillomavirus oncogene expression under hypoxia is mediated by PI3K/mTORC2/AKT signaling
  201. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax
  202. Differential controls of MAIT cell effector polarization by mTORC1/mTORC2 via integrating cytokine and costimulatory signals
  203. Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway
  204. M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis
  205. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth …
  206. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
  207. BYSL contributes to tumor growth by cooperating with the mTORC2 complex in gliomas
  208. A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in …
  209. PP242 counteracts glioblastoma cell proliferation, migration, invasiveness and stemness properties by inhibiting mTORC2/AKT
  210. Alkaline intracellular pH (pHi) activates AMPK–mTORC2 signaling to promote cell survival during growth factor limitation
  211. Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt
  212. Microtopographical cues promote peripheral nerve regeneration via transient mTORC2 activation
  213. Rapamycin and mTORC2 inhibition synergistically reduce contraction‐stimulated muscle protein synthesis
  214. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells
  215. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells
  216. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
  217. mTORC1–S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice
  218. PKBγ/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia
  219. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1
  220. The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
  221. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
  222. The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis
  223. The underlying mechanism of proinflammatory NF-κB activation by the mTORC2/Akt/IKKα pathway during skin aging
  224. mTORC2 signaling is necessary for timely liver regeneration after partial hepatectomy
  225. Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury
  226. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells
  227. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases
  228. mTORC2 affects the maintenance of the muscle stem cell pool
  229. IKK interacts with rictor and regulates mTORC2
  230. Role of mTORC1 and mTORC2 in breast cancer: therapeutic targeting of mTOR and its partners to overcome metastasis and drug resistance
  231. CD146 regulates growth factor-induced mTORC2 activity independent of the PI3K and mTORC1 pathways
  232. eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signaling
  233. DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway
  234. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells
  235. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex
  236. Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice [S]
  237. Rictor/mTORC2 regulates blood‐testis barrier dynamics via its effects on gap junction communications and actin filament network
  238. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo
  239. Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis
  240. Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling
  241. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling
  242. Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways
  243. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells
  244. mTORC1 and mTORC2 differentially regulate cell fate programs to coordinate osteoblastic differentiation in mesenchymal stromal cells
  245. mTORC2 forms iron-clad defense to guard memory
  246. KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice
  247. mTORC2 confers neuroprotection and potentiates immunity during virus infection
  248. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway
  249. mTORC2 promotes cell survival through c-Myc–dependent up-regulation of E2F1
  250. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction
  251. Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTORC2 activation
  252. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
  253. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
  254. mTORC2-mediated PDHE1α nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma
  255. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma
  256. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition
  257. mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission
  258. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism
  259. Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss
  260. mTORC2 facilitates endothelial cell senescence by suppressing Nrf2 expression via the Akt/GSK-3β/C/EBPα signaling pathway
  261. mSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel
  262. Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation
  263. mTORC2 balances AKT activation and eIF2α serine 51 phosphorylation to promote survival under stress
  264. Branched‐chain amino acids prevent insulin‐induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2‐dependent mechanisms
  265. KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis
  266. LPS induces mTORC1 and mTORC2 activation during monocyte adhesion
  267. Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2
  268. mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation
  269. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2
  270. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers
  271. Hetero-oligomerization of Rho and Ras GTPases connects GPCR activation to mTORC2-AKT signaling
  272. mTORC2/Rac1 pathway predisposes cancer aggressiveness in IDH1-mutated glioma
  273. The mTORC2/Akt/NFκB pathway-mediated activation of TRPC6 participates in adriamycin-induced podocyte apoptosis
  274. BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation
  275. Fumonisin B1 induces nephrotoxicity via autophagy mediated by mTORC1 instead of mTORC2 in human renal tubule epithelial cells
  276. Inhibition of mTORC2/RICTOR impairs melanoma hepatic metastasis
  277. mTORC2 phosphorylation of Akt1: a possible mechanism for hydrogen sulfide-induced cardioprotection
  278. Differential regulation of mTORC1 and mTORC2 is critical for 8-Br-cAMP-induced decidualization
  279. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo …
  280. PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of …
  281. CD40-induced signaling in human endothelial cells results in mTORC2-and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo
  282. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism …
  283. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
  284. Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis
  285. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma
  286. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma
  287. Loss of GCN5L1 in cardiac cells disrupts glucose metabolism and promotes cell death via reduced Akt/mTORC2 signaling
  288. PKCβII acts downstream of chemoattractant receptors and mTORC2 to regulate cAMP production and myosin II activity in neutrophils
  289. mTORC2 dictates Warburg effect and drug resistance
  290. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1)
  291. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis …
  292. mTOR modulates resistance to gemcitabine in lung cancer in an mTORC2 dependent mechanism
  293. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2
  294. mTORC2 activation protects retinal ganglion cells via Akt signaling after autophagy induction in traumatic optic nerve injury
  295. mTORC2 deficiency in myeloid dendritic cells enhances their allogeneic Th1 and Th17 stimulatory ability after TLR4 ligation in vitro and in vivo
  296. T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor/mTORC2 protein for proliferative checkpoint …
  297. mTORC1 and mTORC2 play different roles in the functional survival of transplanted adipose‐derived stromal cells in hind limb ischemic mice via regulating …
  298. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway
  299. The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells
  300. Functional impacts of the BRCA1-mTORC2 interaction in breast cancer
  301. Adipocyte-specific mTORC2 deficiency impairs BAT and iWAT thermogenic capacity without affecting glucose uptake and energy expenditure in cold-acclimated mice
  302. … expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 …
  303. Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function
  304. Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling
  305. The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer
  306. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis
  307. Loss of mTORC2 signaling in oligodendrocyte precursor cells delays myelination
  308. The innate immune kinase TBK1 directly increases mTORC2 activity and downstream signaling to Akt
  309. Identification of MΦ specific POTEE expression: Its role in mTORC2 activation via protein-protein interaction in TAMs
  310. mTOR pathway in papillary thyroid carcinoma: different contributions of mTORC1 and mTORC2 complexes for tumor behavior and SLC5A5 mRNA expression
  311. Quantitative proteomics implicates Rictor/mTORC2 in cell adhesion
  312. Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells
  313. The calcineurin variant CnAβ1 controls mouse embryonic stem cell differentiation by directing mTORC2 membrane localization and activation
  314. CUL5-SOCS6 complex regulates mTORC2 function by targeting Sin1 for degradation
  315. mTORC2 suppresses GSK3-dependent snail degradation to positively regulate cancer cell invasion and metastasis
  316. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression
  317. Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors
  318. Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation
  319. Dual mTORC1/mTORC2 inhibition as a host-directed therapeutic target in pathologically distinct mouse models of tuberculosis
  320. Rapamycin‐Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression
  321. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines
  322. Taurine improves low‐level inorganic arsenic‐induced insulin resistance by activating PPARγ‐mTORC2 signalling and inhibiting hepatic autophagy
  323. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
  324. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma
  325. Functional role of mTORC2 versus integrin-linked kinase in mediating Ser473-Akt phosphorylation in PTEN-negative prostate and breast cancer cell lines
  326. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1
  327. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro
  328. Rictor/mTORC2 loss in osteoblasts impairs bone mass and strength
  329. The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation
  330. … resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
  331. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma
  332. Inhibition of the mTORC2 and chaperone pathways to treat leukemia
  333. Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
  334. The GATOR2–mTORC2 axis mediates Sestrin2-induced AKT Ser/Thr kinase activation
  335. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin
  336. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial …
  337. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
  338. Ras functional proximity proteomics establishes mTORC2 as new direct ras effector
  339. mTORC1 and mTORC2 coordinate early NK cell development by differentially inducing E4BP4 and T-bet
  340. mTORC2/RICTOR exerts differential levels of metabolic control in human embryonic, mesenchymal and neural stem cells
  341. mTORC2-PKBα/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis
  342. Coordinate control of host centrosome position, organelle distribution, and migratory response by Toxoplasma gondii via host mTORC2
  343. Polystyrene microplastics disrupt the blood-testis barrier integrity through ROS-Mediated imbalance of mTORC1 and mTORC2
  344. Critical role of mTORC2-Akt signaling in TGF-β1-induced myofibroblast differentiation of human pterygium fibroblasts
  345. Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid
  346. mTORC2 is involved in the induction of RSK phosphorylation by serum or nutrient starvation
  347. Therapeutic Targeting of mTORC2 in mTORopathies
  348. TLR4 counteracts BVRA signaling in human leukocytes via differential regulation of AMPK, mTORC1 and mTORC2
  349. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma
  350. Lithium ameliorates tubule-interstitial injury through activation of the mTORC2/protein kinase B pathway
  351. Active mTORC2 signaling in naive T cells suppresses bone marrow homing by inhibiting CXCR4 expression
  352. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration
  353. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8‐CPT‐2Me‐cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex
  354. mTORC2 negatively controls the maturation process of medullary thymic epithelial cells by inhibiting the LTβR/RANK‐NF‐κB axis
  355. Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells: involving mTORC1 and mTORC2
  356. mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival
  357. Cross-talks via mTORC2 can explain enhanced activation in response to insulin in diabetic patients
  358. Metallothionein Protects the Heart Against Myocardial Infarction via the mTORC2/FoxO3a/Bim Pathway
  359. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells
  360. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood–brain barrier without restriction by ABCB1 and ABCG2
  361. Amplifying mTORC2 signals through AMPK during energetic stress
  362. … inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical …
  363. Insulin-dependent regulation of mTORC2-Akt-FoxO suppresses TLR4 signaling in human leukocytes: relevance to type 2 diabetes
  364. Rictor/mTORC2 involves mitochondrial function in ES cells derived cardiomyocytes via mitochondrial Connexin 43
  365. Down-regulation of placental Cdc42 and Rac1 links mTORC2 inhibition to decreased trophoblast amino acid transport in human intrauterine growth restriction
  366. … between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2
  367. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma
  368. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling
  369. mTORC2 (Rictor) in Alzheimer’s disease and reversal of amyloid-β expression-induced insulin resistance and toxicity in rat primary cortical neurons
  370. mTORC2 regulates multiple aspects of NKT‐cell development and function
  371. Integrity of mTORC2 is dependent on the rictor Gly-934 site
  372. Receptor-Recognized α2-Macroglobulin Binds to Cell Surface-Associated GRP78 and Activates mTORC1 and mTORC2 Signaling in Prostate Cancer Cells
  373. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
  374. Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2)
  375. Hepatic FOXO1 target genes are co-regulated by thyroid hormone via RICTOR protein deacetylation and mTORC2-AKT protein inhibition
  376. mTORC2 activity disrupts lysosome acidification in systemic lupus erythematosus by impairing caspase-1 cleavage of Rab39a
  377. mTORC2 regulates hierarchical micro/nano topography‐induced osteogenic differentiation via promoting cell adhesion and cytoskeletal polymerization
  378. Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation
  379. Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer
  380. Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc
  381. Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating mTORC2 activation in esophageal …
  382. Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and …
  383. Opposing tumor-promoting and-suppressive functions of rictor/mTORC2 signaling in adult glioma and pediatric SHH medulloblastoma
  384. AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival
  385. The Bardet–Biedl syndrome-related protein CCDC28B modulates mTORC2 function and interacts with SIN1 to control cilia length independently of the mTOR complex
  386. Exercise increases phosphorylation of the putative mTORC2 activity readout NDRG1 in human skeletal muscle
  387. Metabolic regulation of T cell development by Sin1–mTORC2 is mediated by pyruvate kinase M2
  388. mTORC2 in the dorsomedial striatum of mice contributes to alcohol-dependent F-Actin polymerization, structural modifications, and consumption
  389. Uropathogenic Escherichia coli infection compromises the blood-testis barrier by disturbing mTORC1-mTORC2 balance
  390. Caspase-2 promotes AMPA receptor internalization and cognitive flexibility via mTORC2-AKT-GSK3β signaling
  391. TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling
  392. Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages
  393. mTORC2 in thymic epithelial cells controls thymopoiesis and T cell development
  394. PtdIns (3, 4, 5) P3-dependent activation of the mTORC2 kinase complex
  395. Wnt5a regulates junctional function of Sertoli cells through PCP-mediated effects on mTORC1 and mTORC2
  396. Over-expression of a retinol dehydrogenase (SRP35/DHRS7C) in skeletal muscle activates mTORC2, enhances glucose metabolism and muscle …
  397. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin
  398. Translationally controlled tumor protein promotes liver regeneration by activating mTORC2/AKT signaling
  399. Calpain‐activated mTORC2/Akt pathway mediates airway smooth muscle remodelling in asthma
  400. Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway
  401. Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling
  402. Resveratrol activates natural killer cells through Akt-and mTORC2-Mediated c-Myb upregulation
  403. Proliferating helper T cells require Rictor/mTORC2 complex to integrate signals from limiting environmental amino acids
  404. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes
  405. Insulin upregulates the expression of epithelial sodium channel in vitro and in a mouse model of acute lung injury: role of mTORC2/SGK1 pathway
  406. Inflammation-induced mTORC2-Akt-mTORC1 signaling promotes macrophage foam cell formation
  407. Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis
  408. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo
  409. BCKA down-regulates mTORC2-Akt signal and enhances apoptosis susceptibility in cardiomyocytes
  410. Dual inhibition of mTORC1 and mTORC2 perturbs cytoskeletal organization and impairs endothelial cell elongation
  411. mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma
  412. mTORC2, the “other” mTOR, is a new player in energy balance regulation
  413. NGF signaling in PC12 cells: the cooperation of p75NTR with TrkA is needed for the activation of both mTORC2 and the PI3K signalling cascade
  414. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways
  415. Transmembrane inhibitor of RICTOR/mTORC2 in hematopoietic progenitors
  416. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling
  417. Therapeutic implication of mTORC2 in oral squamous cell carcinoma
  418. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid …
  419. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in …
  420. Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia
  421. Heat stress-induced PI3K/mTORC2-dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat …
  422. mTORC2 Regulates lipogenic gene expression through PPARγ to control lipid synthesis in bovine mammary epithelial cells
  423. DDR2 induces gastric cancer cell activities via activating mTORC2 signaling and is associated with clinicopathological characteristics of gastric cancer
  424. Shear Stress Increases V–H + -ATPase and Acidic Vesicle Number Density, and p-mTORC2 Activation in Prostate Cancer Cells
  425. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein
  426. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer
  427. Citreoviridin induces myocardial apoptosis through PPAR-γ-mTORC2-mediated autophagic pathway and the protective effect of thiamine and selenium
  428. mTORC2: actin on your memory
  429. Endosomal mTORC2 is required for phosphoinositide-dependent AKT activation in platelet-derived growth factor-stimulated glioma cells
  430. DNA polymerase gamma (Polγ) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling
  431. Alcohol‐induced modulation of rictor and mTORC2 activity in C2C12 myoblasts
  432. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2
  433. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
  434. Liver Reptin/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling
  435. Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
  436. Developmentally spliced PKCβII provides a possible link between mTORC2 and Akt kinase to regulate 3T3-L1 adipocyte insulin-stimulated glucose transport
  437. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8+ effector T cell responses
  438. Protective effect of docosahexaenoic acid on lipotoxicity‐mediated cell death in Schwann cells: Implication of PI3K/AKT and mTORC2 pathways
  439. Physical interaction of estrogen receptor with MnSOD: Implication in mitochondrial O2.− upregulation and mTORC2 potentiation in estrogen-responsive breast cancer …
  440. Estrogen receptor potentiates mTORC2 signaling in breast cancer cells by upregulating superoxide anions
  441. … regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein
  442. UVB-induced inactivation of manganese-containing superoxide dismutase promotes mitophagy via ROS-mediated mTORC2 pathway activation
  443. EBV LMP1-activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties
  444. A germline-specific role for the mTORC2 component Rictor in maintaining spermatogonial differentiation and intercellular adhesion in mouse testis
  445. Deconvolution of mTORC2 “in silico”
  446. Gremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling
  447. The mTORC2/PKC pathway sustains compensatory insulin secretion of pancreatic β cells in response to metabolic stress
  448. The 3.2-Å resolution structure of human mTORC2
  449. mTORC1 and mTORC2 converge on the Arp2/3 complex to promote KrasG12D-induced acinar-to-ductal metaplasia and early pancreatic carcinogenesis
  450. Caffeine inhibits PI3K and mTORC2 in Dictyostelium and differentially affects multiple other cAMP chemoattractant signaling effectors
  451. Loss of mTORC2‐induced metabolic reprogramming in monocytes uncouples migration and maturation from production of proinflammatory mediators
  452. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
  453. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma
  454. Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways
  455. Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma
  456. Gonadotropin releasing hormone activation of the mTORC2/Rictor complex regulates actin remodeling and ERK activity in LβT2 cells
  457. Involvement of Rictor/mTORC2 in cardiomyocyte differentiation of mouse embryonic stem cells in vitro
  458. αMSH prevents ROS-induced apoptosis by inhibiting Foxo1/mTORC2 in mice adipose tissue
  459. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling
  460. Hydrogen peroxide (H2O2) mediated activation of mTORC2 increases intracellular Na+ concentration in the renal medullary thick ascending limb of Henle
  461. 17ss-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling
  462. Heterogeneous nuclear ribonucleoprotein M associates with mTORC2 and regulates muscle differentiation
  463. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast …
  464. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons
  465. Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells
  466. Lysosomal mTORC2/PHLPP1/Akt axis: a new point of control of chaperone-mediated autophagy
  467. mTORC2/Akt activation in adipocytes is required for adipose tissue inflammation in tuberculosis
  468. mTORC2/Rictor is essential for coelomocyte endocytosis in Apostichopus japonicus
  469. mTORC1 and mTORC2 expression levels in oral squamous cell carcinoma: an immunohistochemical and clinicopathological study
  470. mTORC2 puts its shoulder to krebs’ wheel
  471. P27 Promotes TGF-β-Mediated Pulmonary Fibrosis via Interacting with mTORC2
  472. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
  473. Fisetin-induced PTEN expression reverses cellular senescence by inhibiting the mTORC2-Akt Ser473 phosphorylation pathway in vascular smooth muscle cells
  474. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
  475. LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia
  476. The mTORC2 Component Rictor Is Required for Load‐Induced Bone Formation in Late‐Stage Skeletal Cells
  477. Enhancing Acsl4 in absence of mTORC2/Rictor drove β-cell dedifferentiation via inhibiting FoxO1 and promoting ROS production
  478. mTORC1 and mTORC2 play different roles in regulating cardiomyocyte differentiation from embryonic stem cells
  479. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle
  480. Bisphenol S perturbs Sertoli cell junctions in male rats via alterations in cytoskeletal organization mediated by an imbalance between mTORC1 and mTORC2
  481. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W
  482. Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)
  483. mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle–Roles of Rap1 geranylgeranylation and …
  484. Two conserved glycine residues in mammalian and Dictyostelium Rictor are required for mTORC2 activity and integrity
  485. Estrogen receptor alpha and beta regulate actin polymerization and spatial memory through an SRC-1/mTORC2-dependent pathway in the hippocampus of female …
  486. Caffeine inhibits EGF-stimulated trophoblast cell motility through the inhibition of mTORC2 and Akt
  487. Avian reovirus p17 and σA act cooperatively to downregulate Akt by suppressing mTORC2 and CDK2/cyclin A2 and upregulating proteasome PSMB6
  488. microRNA-153 targets mTORC2 component rictor to inhibit glioma cells
  489. Lycopene Protects Keratinocytes Against UVB Radiation‐Induced Carcinogenesis via Negative Regulation of FOXO3a Through the mTORC2/AKT Signaling Pathway
  490. Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway
  491. Phosphoinositide-dependent kinase 1 and mTORC2 synergistically maintain postnatal heart growth and heart function in mice
  492. T-2 toxin exposure induces apoptosis in TM3 cells by inhibiting mammalian target of rapamycin/serine/threonine protein kinase (mTORC2/AKT) to promote Ca2+ …
  493. Delayed tooth movement in Runx2+/− mice associated with mTORC2 in stretch-induced bone formation
  494. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
  495. Hydrophobic motif site-phosphorylated protein kinase CβII between mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy
  496. Mammalian target of rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation
  497. MicroRNA-7-5p regulates human alveolar epithelial sodium channels by targeting the mTORC2/SGK-1 signaling pathway
  498. Stimulation of mTORC2 by integrin αIIbβ3 is required for PI3Kβ-dependent activation of Akt but is dispensable for platelet spreading on fibrinogen
  499. XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts
  500. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma
  501. mTORC2 deficiency alters the metabolic profile of conventional dendritic cells
  502. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2
  503. Effective-components combination improves airway remodeling in COPD rats by suppressing M2 macrophage polarization via the inhibition of mTORC2 …
  504. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant …
  505. Loss of mTORC2 Activity in Neutrophils Impairs Fusion of Granules and Affects Cellular Metabolism Favoring Increased Bacterial Burden in Sepsis
  506. Morin Acts as a USP7 Inhibitor to Hold Back the Migration of Rheumatoid Arthritis Fibroblast‐Like Synoviocytes in a “Prickle1‐mTORC2” Dependent Manner
  507. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades
  508. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model
  509. Inhibition of the IGF-1–PI3K–Akt–mTORC2 pathway in lipid rafts increases neuronal vulnerability in a genetic lysosomal glycosphingolipidosis
  510. Sirt1 Mediates Vitamin D Deficiency-Driven Gluconeogenesis in the Liver via mTORC2/Akt Signaling
  511. Fibroblast growth factor 1 ameliorates adipose tissue inflammation and systemic insulin resistance via enhancing adipocyte mTORC2/Rictor signal
  512. Is dual mTORC1 and mTORC2 therapeutic blockade clinically feasible in cancer?
  513. TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation
  514. Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter
  515. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer
  516. Mdm20 modulates actin remodeling through the mTORC2 pathway via its effect on rictor expression
  517. Comment on “A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation”: building a model of the mTOR signaling network with a …
  518. Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation
  519. The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling
  520. Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1, mTORC2 and protein synthesis in myocytes
  521. GSK3 inhibitor AR-A014418 promotes osteogenic differentiation of human adipose-derived stem cells via ERK and mTORC2/Akt signaling pathway
  522. Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity
  523. mTORC2 Activation Mediated by Mesenchymal Stem Cell-Secreted Hepatocyte Growth Factors for the Recovery of Lipopolysaccharide-Induced Vascular …
  524. mTORC2 coordinates pulmonary artery smooth muscle cell metabolism, proliferation and survival in pulmonary arterial hypertension
  525. Calcium sensing receptor stimulates breast cancer cell migration via the Gβγ-AKT-mTORC2 signaling pathway
  526. Targeting mTORC2/HDAC3 Inhibits Stemness of Liver Cancer Cells Against Glutamine Starvation
  527. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
  528. Enhanced Akt phosphorylation and myogenic differentiation in PI3K p110β-deficient myoblasts is mediated by PI3K p110α and mTORC2
  529. Perspectives on the role of mTORC2 in B lymphocyte development, immunity and tumorigenesis
  530. GPR30‐mediated estrogenic regulation of actin polymerization and spatial memory involves SRC‐1 and PI3K‐mTORC2 in the hippocampus of female mice
  531. Mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 as key signaling intermediates in mesenchymal cell activation
  532. Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS‐induced expression of IL‐12 and IL‐23 in human dendritic cells
  533. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral …
  534. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant …
  535. AMPK and the PI3K-mTORC2-AKT axis shape the mitochondrial integrated-stress-response
  536. … of blood–testis barrier (BTB) dynamics during spermatogenesis via the “Yin” and “Yang” effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2
  537. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2
  538. Role of mTORC2 in biphasic regulation of brown fat metabolism in response to mild and severe cold
  539. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion
  540. KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative breast cancer cells
  541. Rictor/mTORC2 is involved in endometrial receptivity by regulating epithelial remodeling
  542. Structural features of mTORC2 that control substrate-specific activities
  543. mTORC2 steals the spotlight
  544. Omega-3 polyunsaturated fatty acids attenuate fibroblast activation and kidney fibrosis involving mTORC2 signaling suppression
  545. PI3K regulation of the SKP-2/p27 axis through mTORC2
  546. The Deubiquitinase USP39 Promotes ESCC Tumorigenesis Through Pre-mRNA Splicing of the mTORC2 Component Rictor
  547. TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORC2–AKT1–NFAT1–PHLPP2 signaling axis
  548. Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells
  549. Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triple-negative breast cancer via SMAD2/3/4 and mTORC2 signaling
  550. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt
  551. Prohibitin-Mediated Lifespan and Mitochondrial Stress Implicate SGK-1, Insulin/IGF and mTORC2 in C. elegans
  552. Depletion of Ric-8B leads to reduced mTORC2 activity
  553. P-OT002. Alcohol consumption alters the amygdalar protein expression of mTORC2 in male Wistar rats
  554. β-Barrel outer membrane proteins suppress mTORC2 activation and induce autophagic responses
  555. Bladder Cancer Invasion is Mediated by mTORC2-Driven Regulation of Nitric Oxide and Invadopodia Formation.
  556. DNMT1, a novel regulator mediating mTORC1/mTORC2 pathway-induced NGF expression in schwann Cells
  557. Interferon γ (IFNγ) signaling via mechanistic target of rapamycin complex 2 (mTORC2) and regulatory effects in the generation of type II interferon biological …
  558. mTORC2 brings up the rear
  559. Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
  560. Combinatorial Inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant Pheochromocytoma
  561. Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling …
  562. Chronic rapamycin treatment exacerbates metabolism and does not down-regulate mTORC2/Akt signaling in diabetic mice induced by high-fat diet and streptozotocin
  563. … urine in the obstructed kidney promotes urothelial carcinoma cell proliferation, migration, invasion through the activation of mTORC2-AKT and ERK signaling …
  564. … phosphoprotein 1 cooperatively stimulate migration and adhesion of ovine trophectoderm cells via focal adhesion-mTORC2 mediated cytoskeleton reorganization
  565. Polycystin‐1 regulates cell proliferation and migration through AKT/mTORC2 pathway in a human craniosynostosis cell model
  566. Rictor amplification promotes NSCLC cell proliferation through formation and activation of mTORC2 at the expense of mTORC1
  567. … Expression of FK506-binding protein 12-rapamycin complex-associated protein 1 (FRAP1) and regulators and effectors of mTORC1 and mTORC2 complexes in ovine …
  568. Stimulatory effect of insulin on H + -ATPase in the proximal tubule via the Akt/mTORC2 pathway
  569. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity
  570. The mTORC2 Regulator Homer1 Modulates Protein Levels and Sub-Cellular Localization of the CaSR in Osteoblast-Lineage Cells
  571. Halting renal fibrosis: an unexpected role for mTORC2 signaling
  572. Protein phosphatase 6 promotes neurite outgrowth by promoting mTORC2 activity in N2a cells
  573. HIV-1 Nef-POTEE; a novel interaction modulates macrophage dissemination via mTORC2 signaling pathway
  574. Implication of BAG5 downregulation in metabolic reprogramming of cisplatin-resistant ovarian cancer cells via mTORC2 signaling pathway
  575. Inhibition of mTORC2 enhances UVB-induced apoptosis in keratinocytes through a mechanism dependent on the FOXO3a transcriptional target NOXA but …
  576. … (TNF-α)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) …
  577. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1
  578. Selective obstruction of the mTORC2 complex by a naturally occurring cholestane saponin (OSW-1) for inhibiting prostate cancer cell growth
  579. mTORC2: The other facet of mTOR
  580. Na+ influx via Orai1 inhibits intracellular ATP-induced mTORC2 signaling to disrupt CD4 T cell gene expression and differentiation
  581. c-Jun N-terminal kinase (JNK)–mediated induction of mSin1 expression and mTORC2 activation in mesenchymal cells during fibrosis
  582. Rictor overexpression and mTORC2 signaling in chronic lymphocytic leukemia
  583. Coinhibition of mTORC1/mTORC2 and RhoA/ROCK pathways prevents chronic rejection of rat cardiac allografts
  584. mTORC2 deficiency in cutaneous dendritic cells potentiates CD8+ effector T cell responses and accelerates skin graft rejection
  585. Architecture of the human mTORC2 core complex
  586. Impaired mTORC2 signaling in catecholaminergic neurons exaggerates high fat diet-induced hyperphagia
  587. Erratum to: Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition
  588. High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay
  589. When mTORC2-AKT signaling meets cell polarity
  590. Basal mTORC2 activity and expression of its components display diurnal variation in mouse perivascular adipose tissue
  591. Role for mTORC2 in insulin resistance
  592. Author correction: Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
  593. In B cells, phosphatidylinositol 5-phosphate 4-kinase–α synthesizes PI (4, 5) P2 to impact mTORC2 and Akt signaling
  594. Targeting mLST8 in mTORC2-dependent cancers
  595. Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication
  596. mTORC2 takes the longevity stAGE
  597. Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model
  598. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells
  599. mTORC2 contributes to murine lupus
  600. Imidazo [1, 5-a] pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2
  601. The antipancreatic cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2
  602. mTORC1 and mTORC2 in energy homeostasis
  603. Dual inhibition of mTORC1/mTORC2 induces apoptosis of mantle cell lymphoma by preventing rictor mediated AKTS473 phosphorylation by potentiating AKT2 …
  604. In vivo and in vitro impact of miRNA-153 on the suppression of cell growth apoptosis through mTORC2 signaling pathway in breast cancer
  605. Negative regulation of mTORC2 by glycogen synthase kinase-3β: an adaptive process to stress with an anticancer therapeutic potential?
  606. XPLN is a novel regulator of mTORC2
  607. Development of monoclonal antibody against protein Rictor, a component of the mTORC2 complex
  608. mTORC2 loss in oligodendrocyte progenitor cells results in regional hypomyelination in the central nervous system
  609. Impact of green tea epigallocatechin-3-gallate on HIF1-α and mTORC2 expression in obese women: anti-cancer and anti-obesity effects?
  610. Down regulation of Peroxiredoxin-3 in 3T3-L1 adipocytes leads to oxidation of Rictor in the mammalian-target of rapamycin complex 2 (mTORC2)
  611. Response to Comment on “A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation”: Building a Model of the mTOR Signaling …
  612. Cardiomyocyte targeted overexpression of IGF1 during detraining restores compromised cardiac condition via mTORC2 mediated switching of PKCδ to PKCα
  613. Differential role of rapamycin in epidermis-induced IL-15-IGF-1 secretion via activation of Akt/mTORC2
  614. Sin1–mTORC2 signaling drives glycolysis of developing thymocytes
  615. c-FLIP links mTORC2 to apoptosis
  616. mTORC2 is the Primary Target for Simvastatin-Associated Toxicity in C2C12 Cells and in Mouse Skeletal Muscle
  617. Disruption of DEPTOR/mTORC1/mTORC2 signaling cascade using a novel selective mTOR kinase inhibitor AZD8055 results in growth arrest and apoptosis in …
  618. Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
  619. Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.
  620. Dynamic modelling of the PI3K/mTOR signalling network uncovers biphasic dependence of mTORC1 activation on the mTORC2 subunit Sin1
  621. OSI-027 alleviates rapamycin insensitivity by modulation of mTORC2/AKT/TGF-β1 and mTORC1/4E-BP1 signaling in hyperoxia-induced lung injury infant rats
  622. Myeloid Dendritic Cell-Specific mTORC2 Deficiency Enhances Alloreactive Th1 and Th17 Cell Responses and Skin Graft Rejection.: Abstract# 584
  623. Targeting the mTORC2 signaling complex in B cell malignancies
  624. Mitochondrial Bioenergetics Profile With Different Mechanistic Target of Rapamycin Complexes (mTORC1/mTORC2) Inhibitors in Pancreatic Beta-Cell Lines (Beta-TC …
  625. mTORC2 Drives ZFX-mediated Ganglioside Biosynthesis to Promote Breast Cancer Progression.
  626. Genetic immunodeficiency and autoimmune disease reveal distinct roles of Hem1 in the WAVE2 and mTORC2 complexes
  627. Divergent Roles of Macrophage mTORC1 and mTORC2 Signaling in Atherosclerosis
  628. Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro
  629. P-122: Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO
  630. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol
  631. Discovery and optimization of 5, 7-dihydro-6H-pyrrolo [2, 3-d] pyrimidin-6-one derivatives as mTORC1/mTORC2 dual inhibitors
  632. 3D structure determination and validation of mTORC2 using computational modeling techniques
  633. Role of mTORC2 and nitric oxide in bladder cancer invasion.
  634. Response to Comment on Sato et al. Improving Type 2 Diabetes Through a Distinct Adrenergic Signaling Pathway Involving mTORC2 That Mediates Glucose Uptake …
  635. LST8 level controls basal p70 S6 kinase and Akt phosphorylations, and mTORC1 and mTORC2 negatively regulate each other by competing for association with …
  636. PTH (1‑34) activates the migration and adhesion of BMSCs through the rictor/mTORC2 pathway
  637. EBV LMP1-activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Formation
  638. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.
  639. The Role of CGRP Inhibition and High-Intensity Interval Training (HIIT) on mTORC2 and VEGF Gene Expression in The Hippocampal Tissues of Male Wistar Rats
  640. mTORC2 mediate FLCN-induced HIF2α nuclear import and proliferation of clear cell renal cell carcinoma
  641. OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase Inhibitor is mechanistically distinct from rapamycin
  642. Direct physical interaction of active Ras with mSIN1 regulates mTORC2 signaling
  643. Novel Upstream Activation of mTORC2 by the Innate Immune Kinase TBK1
  644. Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia
  645. AiCAR Induces AMPK, mTORC2, and Akt Activity in Myotubes
  646. mTORC2 is an in vivo hydrophobic motif kinase of S6 Kinase 1.
  647. Prostaglandin E2 induces activation of mTORC1 and mTORC2 in mast cells: selective utilization of mTORC2 for the regulation of chemotaxis and mediator release …
  648. The mTORC2 Regulator homer1 Modulates Protein Levels and Sub-Cellular Localization of the CaSR in Human Osteoblasts.
  649. Xpln Negatively Regulates Sparc Expression By Targeting mTORC2 In Human Lung Fibroblasts
  650. mTORC2 mediates SDF-1α/CXCL12-induced angiogenesis
  651. Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTORC2 activation
  652. Glycolytic Bias in mTORC2 Deficient Dendritic Cells Potentiates Antigen-Specific Immunity and Accelerates Graft Rejection
  653. mTORC2-IRF4 mediated metabolic reprograming is essential for macrophage alternative activation
  654. mTORC2 controls dendritic arbor development through Akt-mTORC1-p70S6K pathway
  655. Abstract# 4770: Characterization of AZD8055, a potent selective inhibitor of mTORC1 and mTORC2 kinase
  656. Evidence for increased mTORC1 and mTORC2 signaling in human thoracic aortic aneurysm
  657. Influence of co-inhibiting mTORC2 and HSP90 on proliferation apoptosis of multiple myeloma cells
  658. Histone deacetylase inhibition with LBH589 inhibits the rapamycin insensitive Rictor-mTOR (mTORC2) complex and translation initiation factor eIF4E activation in …
  659. Anti-fibrotic effect of combined mTORc1 and mTORC2 inhibition in bronchiolitos obliterans
  660. Hitting the TORget: curcumin disrupts mTORC1 and mTORC2
  661. Abstract B49: mTORC2 directs breast morphogenesis through Rictor-dependent PKCα/Rac1 signaling independent of Akt
  662. SEX AND TISSUE SPECIFIC ROLES OF mTORC2 IN HEALTHSPAN, METABOLISM, AND SURVIVAL
  663. Rapamycin analogs reduce mTORC2 signaling and inhibit AKT activation in AML.
  664. Differential Modulation of mTORC1 and mTORC2 Signaling by Rapamycin During Pro-Arteriosclerotic Differentiation of Mesenchymal Stem Cells: 1485
  665. Therapeutic implications of mTORC1 and mTORC2 inhibitors in genetically heterogeneous glioblastoma
  666. Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.
  667. Activin signaling regulates autophagy and cardiac aging through mTORC2
  668. mTORC2 combats cellular stress and potentiates immunity during viral infection
  669. Morphoproteomics of mTORC2 pathway as resistance signature and activated ERK and STAT3 prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma …
  670. Rictor/mTORC2 is a critical mediator of cardiac hypertrophy and survival in response to pressure overload
  671. … S perturbs Sertoli cell junctions in male rats via alterations in cytoskeletal organization mediated by an imbalance between mTORC1 and mTORC2“[Sci. Total Environ …
  672. Is Ang II-mediated mTOR/S6K1 activation in proximal tubule cells mTORC2-dependent?
  673. Anticancer activity of the mTOR inhibitor (everolimus) and dual mTORC1/mTORC2 Inhibitor (AZD2014) on mouse lymphocytic leukemia both in vitro and in vivo
  674. Dual targeting of PI3K/mTOR leads to MEK/ERK over-activation in leiomyosarcoma through suppression of mTORC2 inhibition
  675. Abstract B146: XL388: a novel, selective, orally bioavailable mTORC1 and mTORC2 inhibitor that demonstrates pharmacodynamic and antitumor activity in multiple …
  676. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis1, 2
  677. Role of Ras in Regulating mTORC2 Activity and Function in Breast Cancer Cell Migration
  678. The Role of mTORC1/RagGTPase and IGF1R/mTORC2/Akt Pathways and the Response of Diffuse Congenital Hyperinsulinism to Sirolimus
  679. mTORC2 tips the balance in cell survival
  680. 3-Benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2 (3H)-one suppresses FcεRI-mediated mast cell degranulation via the inhibition of mTORC2-Akt signaling
  681. … to: Effective-components combination improves airway remodeling in COPD rats by suppressing M2 macrophage polarization via the inhibition of mTORC2 activity
  682. Step1: mTORC2 activation
  683. Selective inhibition of mTORC2 by disruption of mLST8 scaffolding function
  684. Re: Inhibition of mTORC2 but not mTORC1 Up-Regulates E-Cadherin Expression and Inhibits Cell Motility by Blocking HIF-2α Expression in Human Renal Cell …
  685. Muscle‐specific deletion of mTORC2 (Rictor) blocks insulin stimulated Akt Ser 473 phosphorylation and impairs submaximal but not maximal insulin induced glucose …
  686. The Lipid Handling Capacity of Subcutaneous Fat Requires mTORC2 during Development
  687. Function of mTORC2 and its roles in hematological malignancies
  688. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
  689. … Dual PI3K/mTORC1/C2 Inhibition on Long-Term Cultured Primary Human Acute Lymphoblastic Leukemia (ALL) Cells Implicate a Distinct Role of mTORC2.
  690. Investigating mTORC2/AKT-mediated regulation of FOXO1: a novel therapeutic strategy for chronic lymphocytic leukaemia?
  691. TMBIM6 regulates the assembly and activation of mTORC2
  692. Hepatic Activation of FOXO3 Is Associated with Pentose Phosphate Pathway Activation as Well as mTORC2-Akt Signaling and Enhances Oxidative Damage …
  693. mTORC2 controls potassium secretion
  694. mTORC2 Deficiency in CD11c+ Dendritic Cells Promotes Acute Kidney Injury
  695. Regulation of the mammalian target of rapamycin complex 2 (mTORC2)
  696. Correction: Translationally controlled tumor protein promotes liver regeneration by activating mTORC2/AKT signaling
  697. Hyper-Activation of Mutant KRAS Drives Redox-Dependent Cell Death Involving mTORC2/Akt Signaling and Mitochondrial Morphology Changes
  698. mTORC2 in T Lymphocyte Development and Proliferation
  699. mTORC2-regulated genes transcription
  700. mTORC2 IN THE REGULATION OF MAMMALIAN LONGEVITY
  701. Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
  702. mTORC1 and mTORC2 regulate distinct aspects of glutamatergic synaptic transmission
  703. High glucose up-regulates MMP-1 expression in endothelial cells via mTORC2-PKM2 pathway
  704. OSI-027, a dual mTORC1/mTORC2 inhibitor, induces autophagy in cancer cells
  705. Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2 inhibitor, in tumor and surrogate tissues: Results from the expansion phase of a first-in-man …
  706. Development of RNAi technology to selectively inhibit mTORC2 in breast cancer
  707. Regulation of mammalian target of rapamycin complex 2 (mTORC2) signaling in NF2-deficient target cell types
  708. Promoting Fibroblast Migration with mTORC2
  709. Knockdown of UBXN2A Protein Induces Colorectal Cancer Metastasis Through Up-Regulation of the mTORC2 Signaling Pathway
  710. mTORC2 is a promising therapeutic target in epithelial ovarian cancer
  711. Role of ARHGEF3 as a GEF and mTORC2 Regulator.
  712. Genetic immunodeficiency and autoimmune disease reveals a WRC-independent role for Hem1 in mTORC2 regulation
  713. publisher correction: mTORC1 and mTORC2 Differentially Regulate Cell Fate Programs to Coordinate Osteoblastic Differentiation in Mesenchymal Stromal Cells
  714. mTORC2 in Dendritic Cells Restrains mTORC1-regulated Metabolic Activity and Their T Cell Stimulatory Function in Transplantation
  715. PS1174 mTORC2 ACTIVATION AND AKT NUCLEAR LOCALIZATION UNDER HYPOXIA COULD SUSTAIN THE LEUKEMIA CANCER STEM CELLS
  716. Analysis of mTORC2 in Regulating Aging, Metabolism and Cardiac Disease in Drosophila melanogaster
  717. Loss of mTORC1 & mTORC2 but nor mTORC1 or mTORC2 leads to reduction in cone function.
  718. Elucidating the role of mTOR complexes (mTORC1 and mTORC2) in normal haemopoiesis and in Chronic Lymphocytic Leukaemia
  719. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
  720. mTORC2 promotes tumor growth via lipid synthesis
  721. mTORC2 balances Akt activation and eIF2α serine 51 phosphorylation to promote survival under stress.
  722. Inhibition of mTORC2 Upregulates PDGFRs Expression and Contributes to the Development of Pulmonary Hypertension
  723. mTORC2 Akt-ing at the Ribosome
  724. Enhanced pro-inflammatory profile and Th17 alloresponse by targeting mTORC2 in DC (P2138)
  725. mTORC2 Facilitates the Maturation of Protein Kinase C by a Phosphorylation‐Independent Mechanism
  726. Molecular Modeling Studies of Urea-morpholinopyrimidine Analogues as Dual Inhibitors of mTORC1 and mTORC2 Using 3D-QSAR, Topomer CoMFA and Molecular …
  727. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2
  728. The Role of the New mTOR Complex, mTORC2, in Autism Spectrum Disorders
  729. AMPK-RUNX2-mTORC2 axis involved in EMT of MDA-MB-231 breast cancer cells
  730. The regulation of mTORC2 kinase activity and complex integrity
  731. Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
  732. Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways
  733. PP2Cδ Controls the Differentiation and Function of Dendritic Cells Through Regulating the NSD2/mTORC2/ACLY Pathway.
  734. mTORC2 suppresses GSK3-dependent, but b-TrCP-independent, Snail degradation, contributing to positive regulation of cancer cell invasion and metastasis
  735. The mTORC2 target Akt is regulated in response to glutamine metabolite levels
  736. mTORC2 Regulates the Maturation of Protein Kinase C by Folding and Phosphorylation
  737. mTORC2 enhances flux through the hexosamine biosynthetic pathway by regulation of GFAT1 expression
  738. TRIM7, a Novel Binding Protein of the mTORC2 Component Sin1
  739. mTORC2 Regulation of the Hexosamine Biosynthetic Pathway (HBP) in Response to Nutrients
  740. Differential Metabolic Sensitivity of mTORC1-and mTORC2-Dependent Overgrowth
  741. The Role of mTORC2 and Ribosomal Protein S6 in Cardioprotective Signaling
  742. Abstract C66: Role of mTORC1 and mTORC2 in multiple myeloma and their targeting with CC214.
  743. mTORC1 and mTORC2 differentially regulate the development of NK cells
  744. Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression
  745. Understanding the role of mTORC1 and mTORC2 in embryonic and adult myogenesis
  746. DOCA-Salt-Induced Endothelial Cell Stiffening Occurs Via mTORC2/SGK1 mediated Regulation of EnNaC
  747. Differential regulation of mTORc1 and mTORC2 by expression of BTG2/TIS21/PC3 inhibits breast cancer cell growth and malignancy
  748. mTORC1 and mTORC2 expressions in the oral squmous cell carcinoma: an immunohistochemical and clinicopathological study
  749. P101 The effect of rapamycin in cardiac mTORC2-deficient mice under pressure overload conditions.
  750. The role of mTORC1 and mTORC2 in UVB‐induced
  751. A high throughput screening assay to identify mTORC1 and mTORC2 inhibitors
  752. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
  753. uPAR and mTORC2 as coupled targets for therapeutics development in bladder cancer.
  754. To examine the combinatorial therapeutic effects of EGFR inhibitor and mTORC2 inhibitor for treatment of pancreatic cancer
  755. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma
  756. Distinct and common functions of mTORC1 and mTORC2 in Purkinje cells
  757. mTORC2 controls T-cell receptor processing and surface expression during thymocyte development (115.18)
  758. The mTORC2 component RICTOR plays a key role in lung cancer cell growth
  759. Inhibition of mTORC2 induces cell cycle arrest and enhances the cytotoxicity of
  760. mTORC2 modulates αβT-cell receptor processing and surface expression during thymocyte development (P4414)
  761. Assessment of the Role of Endothelial mTORC2 in FGF2-induced Angiogenesis in vivo
  762. Lipid Activates mTORC1 and mTORC2 in the Absorption of Dietary Triglycerides
  763. Inhibition of mTORC2/Akt signaling to enhance the therapeutic potential of CD8 T cells
  764. mTORC2 helps brown adipose tissue fuel up
  765. ACTR-36. A Single Arm Phase 2 Study of the Dual Mtorc1/mTORC2 Inhibitor Vistusertib Provided on an Intermittent Schedule FOR Neurofibromatosis 2 Patients with …
  766. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss
  767. Phosphorylation of Protein Kinase Akt by mTORC2 in Peripheral Blood Mononuclear Cells of Patients with Cancer and Diabetes.
  768. Dissecting the roles of mTORC1 and mTORC2 in the mouse heart
  769. mTORC2 Regulates Energy Metabolism, Proliferation And Survival Of Vascular Smooth Muscle Cells In Pulmonary Arterial Hypertension
  770. Regulation of FoxO1 by mTORC2 negatively controls Toll-like receptor responses (111.24)
  771. Comment on prognostic and therapeutic implications of mTORC2 and rictor expression in human breast cancer
  772. Characterisation of a new mechanism of ATR/Chk1 regulation in breast cancer: role of mTORC2
  773. Hepatic activation of FOXO3 regulates mTORC2-Akt and enhances oxidative damage-associated hepatocellular carcinogenesis
  774. UBXN2A inhibits tumor invasion and metastasis by targeting the mTORC2-VEGF pathway
  775. Interaction with phospho-eIF4E commits S6 Kinase 1 for mTORC2 and PHLPP1 mediated activation
  776. Therapeutic Suppression of mTORC2 Signaling Reduces Salt-induced Hypertension and Kidney Injury in SS Rats
  777. … MODELS OF PULMONARY HYPERTENSION: NOVEL TARGETS AND PATHWAYS: Dual Mtorc1/mTORC2 Inhibitor Pp242 Induces mTORC2-Specific Bim-Dependent …
  778. mTORC1 and mTORC2 interact with each other to regulate NK cells maturation and effector functions
  779. The role of mTORC2 in mammary morphogenesis and HER2-mediated tumorigenesis
  780. Myeloid DC-specific mTORC2 deficiency enhances Th1 and Th17 immunologic responses (IRC5P. 472)
  781. Comment on Sato et al. Improving Type 2 Diabetes Through a Distinct Adrenergic Signaling Pathway Involving mTORC2 That Mediates Glucose Uptake in Skeletal …
  782. Effects of mTORC2 on Ovine Conceptus Elongation and Implantation.
  783. Manganese superoxide dismutase regulates mTORC2 mediated UVB-induced mitophagy
  784. 1806-P: Vitamin D Deficiency Impairs mTORC2/Akt Signaling through Downregulating SIRT1 and Results in Increased Hepatic Gluconeogenesis
  785. mTORC1 and mTORC2 regulation of tumor cell growth and survival assessed using small interfering RNA
  786. Rictor/mTORC2 regulates mouse T-all development via FoxO3a
  787. mTORC2 activation determines the retinal ganglion cell fate via Akt signaling after autophagy induction in traumatic optic nerve injury
  788. Inflammation-induced mTORC2-Akt-mTORC1 signaling promotes macrophage foam cell formation
  789. Interrogating cellular metabolism reveals mTORC2 as a new biomarker to stratify epidermal growth factor receptor-mutant non-small cell lung cancer
  790. TAK228, a kinase inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer model
  791. MEDIATING THE mTORC2-DEPENDENT SURVIVAL RESPONSE TO UVB EXPOSURE THROUGH NEGATIVE REGULATION OF THE TUMOR SUPRESSOR …
  792. mTORC2 Regulates Adaptive Cell Fate Programs and Protects Mesenchymal Progenitors From Osteoblastic Transformation.: Abstract# C1572
  793. The Differential Regulation of Monocyte Derived and Tissue Resident Alveolar Macrophages by mTORC2 Promotes Lung Fibrosis
  794. The mTORC2/PKC pathway sustains compensatory insulin secretion of pancreatic β cells in response to metabolic stress General subjects
  795. Disruption of mTORC2 Integrity Underlies Increased Myocardial Susceptibility to Ischemia/reperfusion Injury in Chronic Renal Failure
  796. Chaetoglobosin K, a dual Akt and JNK inhibitor, modulates Akt phosphorylation in an mTORC2 independent manner
  797. mTORC1 and mTORC2 regulate cell proliferation in Glioblastoma multiforme
  798. mTORC2 negatively regulates DC PD-L1 and IL-10 through SOCS3 and STAT3 (172.34)
  799. mTORC2 protein-mediated protein kinase B (Akt) serine 473 phosphorylation is
  800. PINK1/BRPK inhibits apoptotic cell death and enahances cellular invasiveness through an activation of mTORC2 pathway
  801. Hyperuricemia driven pancreatic β-cell dysfunction through Rictor, a subunit of mTORC2
  802. Rictor/mTORC2 drives formation, progression and therapeutic resistance of HER2-amplified breast cancers
  803. Extracellular nutrients are required to maintain oncogenic signaling in brain cancer–a critical role for mTORC2
  804. Abstract C270: In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor.
  805. Endothelial mTORC2 deficiency inhibits tumor angiogenesis, tumor progression and metastasis in non-small cell lung cancer (NSCLC)
  806. Abstract A118: The mTORC2 component Rictor directs branching morphogenesis and survival in the mammary epithelium
  807. Deletion Of The Alpha Subunit Of EnNaC And mTORC2 Inhibition Attenuate DOCA-salt-induced Endothelial Cell And Vascular Stiffness.
  808. HYPER-ACTIVATION OF MUTANT KRAS DRIVES REDOX-DEPENDENT CELL DEATH INVOLVING mTORC2/AKT SIGNALING AND MITOCHONDRIAL …
  809. Dyrk1b Displaces Fkbp12 from mTORC2, Causes its Activation and Triggers De Novo Lipogenesis: Implications for the Treatment of Diet-Induced Fatty Liver Disease
  810. The Impact of mTORC2 Signaling on the Initiation and Progression of KRAS-Driven Pancreatic Neoplasias: A Dissertation
  811. MTORC1 and mTORC2 control normal and neoplastic mast cell homoeostasis through regulation of cell division rather than maintenance of survival (151.20)
  812. Anti-CD44 Antibodies Inhibit Both mTORC1 and mTORC2 Activities in Acute Myeloid Leukemia.
  813. Isolated Human Lung Alveolar Epithelial Cells In Culture Change In MTORC1 And mTORC2 Expression And Signaling With Time
  814. The role of endothelial Rictor (mTORC2) in angiogenesis in vivo and in vitro
  815. AB0115 Influence of mTORC2/akt on the cell viability in rheumatoid arthritis fibroblast-like synoviocytes
  816. Rictor/mTORC2 regulates blood-testis barrier and spermatogenesis in mice
  817. Cytochrome p450 3a5 manipulates the progression of hepatocellular carcinoma via selectively targeting ros/mTORC2/p-akt (s473) signaling
  818. Sin1-mTORC2 regulation of the ontogeny and function of innate lymphoid cells
  819. Abstract A24: CD146-Rictor interaction reveals a pathway linking mTORC2 activation with extracellular stimuli
  820. The role of hypothalamic mTORC1 and adipose tissue mTORC2 in organismal energetics
  821. Abstract C59: Estradiol and mTORC2 orchestrate to enhance prostaglandin biosynthesis andtumorigenesis in tuberous sclerosis complex
  822. Rictor Acetylation Promotes mTORC2-mediated Akt Phosphorylation
  823. mTORC2 controls neuron size and Purkinje cell morphology independent of mTORC1
  824. Abstract B1: Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth
  825. Retraction: Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell …
  826. Targeting the mTORC2/HIF-2alpha/p53 pathway in clear cell renal cell carcinoma.
  827. Rictor plays a critical role in bone mass and strength with the involvement of mTORC2 pathway in osteoblasts
  828. Role for Rictor/mTORC2 Signaling in Mediating TGFb1‐induced Fibroblast Activation and Kidney Fibrosis
  829. MAPKAP1 (Sin1), a Key Component of the mTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid …
  830. mTORC2 directs breast morphogenesis through Rictor-dependent PKCα/Rac1 signaling independent of Akt
  831. The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models
  832. Epstein Barr virus-encoded LMP1 activates the mTORC2 signaling pathway to reprogram glucose metabolism in nasopharyngeal epithelial cell
  833. PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC)
  834. Discovery of a new class of mTOR inhibitors reveals rapamycin-resistant outputs of mTORC1 and mTORC2
  835. The Calcineurin Variant CnAb1 Controls Mouse Embryonic Stem Cell Differentiation by Directing mTORC2 Membrane Localization and Activation
  836. Brain without Rictor: mTORC2 signaling regulates central dopamine homeostasis
  837. Leucine Pulses during Long‐term Continuous Feeding Enhance mTORC1 and mTORC2 Activation in Skeletal Muscle of Neonatal Pigs
  838. Regulation of endothelial cell proliferation of infantile hemangioma through mTORC2 and NDRG1 signaling pathways
  839. Strategies to’Hydrophobize’Systemic siRNA Vectors and Selectively Inhibit mTORC2 in Breast Tumors Through RNA Interference
  840. Abstract IA11: Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming
  841. Targeting PI3K/mTOR leads to MEK/ERK over-activation in pancreatic cancer through suppression of mTORC2
  842. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo
  843. The role of mTORC1 and mTORC2 in hypoxia-induced HIF-1 α stabilization and endothelial proliferation
  844. A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation xmpMM: DocumentID: uuid: 13a28f85-cbc5-4bad-9317-04e8711240fe Last-Save …
  845. Impacto del té verde epigalocatequina-3-galato en la expresión de HF1-α y mTORC2 en mujeres obesas:¿ efectos anticancerígenos y antiobesidad?
  846. Potassium Can Regulate Its Own Excretion in Collecting Duct Cells: Role of mTORC2, SGK1 and ENaC
  847. Inhibitory effects of resveratrol on the proliferation, migration and angiogenesis of HUVECs through targeting mTORC2/Rictor
  848. Ubiquitin C-Terminal Hydrolase L1 Balances mTORC1 and mTORC2 Activities in Myotubes and Oxidative Muscle Fibers
  849. Abstract B10: Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in tuberous sclerosis complex
  850. Female Sex-related Cardioprotection Relies on Estrogen Receptor-beta, mTORC1, and mTORC2 Activities
  851. Myeloid dendritic cell-specific mTORC2 deficiency enhances Th1 and Th17 cell responses and inhibits B16 melanoma growth (TUM6P. 959)
  852. Protein Kinase C-Theta Interacts with mTORC2 and Vimentin to Limit Regulatory T-Cell Function
  853. The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells
  854. Hepatic c-Jun overexpression metabolically reprograms cancer cells through mTORC2/AKT pathway
  855. Akt-mTORC2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers.
  856. … TARGETS IN PULMONARY HYPERTENSION: INSIGHTS FROM TRANSLATIONAL AND PRECLINICAL STUDIES: Nox4 Regulates mTORC2-Akt Signaling And …
  857. Fatty acid elongase‐5 (Elovl5) regulates the mTORC2‐FoxO1 pathway in obese‐diabetic C57BL/6J mice
  858. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer
  859. The mTORC2 Component Rictor Confers Cisplatin Resistance in Human Ovarian Cancer Cells
  860. H2S‐induced cardiac protection is caused by activation of mTORC2/Akt/Bim pathway in an isolated rat heart ischemia/reperfusion model
  861. KLF4 Regulates Self-Renewal of Leukemic Stem Cells in Chronic Myeloid Leukemia By Repressing Gbl Expression and Altering mTORC2 Activity
  862. GW28-e1056 The Valosin-Containing Protein Attenuates Chronic Pressure Overload-induced Cardiac Remodeling and Heart Failure via Activating mTORC2 Pathway
  863. Concomitant Inhibition of mTORC1 and mTORC2 in Dendritic Cells Reduces SOCS3 Expression Resulting in Enhanced Immunoregulatory PD-L1 Expression and IL …
  864. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes.: Phospholipase D and mTOR in myogenesis
  865. mTORC1 inhibition with rapamycin or LY294002 alone but not in combination leads to AKT phosphorylation via mTORC2 in melanoma cells
  866. Type‐I interferon‐mediated Akt/mTORC2 signaling regulates autophagy and inflammasome activation in mouse liver injury/sepsis model
  867. The Valosin-containing Protein Attenuates Chronic Pressure Overload-induced Cardiac Remodeling and Heart Failure via Activating mTORC2 Pathway
  868. An insulin-independent pathway including β-adrenoceptors and mTORC2 that translocates GLUT4 and increases glucose uptake in skeletal muscle
  869. Rapamycin protects livers from ischemia and reperfusion Injury via both autophagy induction and mTORC2-Akt activation
  870. mTORC2 Promotes Lipid Storage and Suppresses Thermogenesis in Brown Adipose Tissue in Part Through AKT-Independent Regulation of FoxO1: A Dissertation
  871. MTORC1 AND mTORC2 PLAY DIFFERENT ROLES IN THE FUNCTIONAL SURVIVAL OF TRANSPLANTED ADIPOSE-DERIVED STROMAL CELLS IN HINDLIMB …
  872. Selective regulation of macrophages differentiation and function by mTOR and metabolic reprogramming: mTORC2 regulates peritoneal tissue-resident macrophages …
  873. A phase i dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in …
  874. Membrane Tension Acts Through PLD2 and mTORC2 to Limit Actin Network Assembly During Neutrophil Migration
  875. Abstract A2: Selective inhibition of mTORC1/mTORC2 sensitizes prostate cancer cells to the effects of AR or IGF-1R/IR antagonists, providing an approach to …
  876. Regulating effect of recombinant lentivirus silencing rictor gene on mTORC2/SGK1 signal pathway and pulmonary alveolar epithelial sodium ion channel
  877. Abstract B27: Superoxide anion O2.-mediated activation of mTORC2 by estrogen receptor in breast cancer cells: Role of acetylation dependent inhibition of MnSOD
  878. Abstract LB-134: mTORC2 regulates the amount of cell surface receptors via its role in protein processing.
  879. … Integrin Mediates Insulin-like Growth Factor-1 Induction of Aortic Smooth Muscle Alpha-Actin Expression Through a PI3K/mTORC2/eIF4E Translational Mechanism
  880. Conditional Ablation of the mTORC2 Component Rictor in Male Germline Reveals a Differential Requirement for Ensuring Spermatogonia Differentiation and …
  881. PO-484 Immunohistochemical analysis of mTORC1 and mTORC2-related proteins in renal cell carcinoma of kidney transplant recipients
  882. CD3/CD28 Co-Stimulated Activation of PI3K-mTORC2-AKT Metabolic Programming Augments Granzyme B Expression and Direct Cytotoxicity in Expanded Human …
  883. FT-1518, a new generation selective and potent mTORC1 and mTORC2 inhibitor: an in vitro and in vivo profile
  884. 133-OR: Dyrk1b Is a Nutrient-Sensing Protein That Triggers De Novo Lipogenesis by Activating mTORC2 Complex: Implication for the Treatment of Type 2 Diabetes
  885. Corrigendum: Omega-3 Polyunsaturated Fatty Acids Attenuate Fibroblast Activation and Kidney Fibrosis Involving mTORC2 Signaling Suppression
  886. Abstract# 1839: OXA-01, a selective inhibitor of mTORC1/mTORC2, enhances apoptosis induced by chemotherapeutic agents through inhibition of Akt …
  887. mTOR complex 2 (mTORC2) regulation of hepatic gene expression
  888. 300 A COMPARISON OF KU0063794, A DUAL MTORC1 AND mTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS
  889. The mammalian target of rapamycin complex 2 (mTORC2) negatively regulates the innate inflammatory response
  890. Abstract# 3711: Superior cellular anti-tumor effects of a dual mTORC1/mTORC2 kinase inhibitor OXA-01 relative to the mTORC1 inhibitor rapamycin
  891. Abstract# 2371: A VEGF-C/Neuropilin 2 axis induces a mTORC2 mediated pathway to protect prostate cancer cells from oxidative stress.
  892. Abstract LB-207: mTORC2/Akt signaling is modulated by noncanonical mitochondrial Notch1/PINK1 interaction in myc-amplified medulloblastoma tumorigenesis
  893. mTOR complex 2 (mTORC2) positively regulates Mcl-1 stability by suppressing GSK3-dependent and FBXW7-mediated proteasomal degradation of Mcl-1
  894. Activation of mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) is required for retinal ganglion cell dendrite regeneration after axonal injury.
  895. Abstract# 2856: mTORC1 and mTORC2 involvement in activation of MAPK pathway via a PI3K/AKT-dependent feedback loop influences glioblastoma multiforme …
  896. Abstract P5-07-06: A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells
  897. Mechanistic Target of Rapamycin Complex 2 (mTORC2) regulation of the primary human trophoblast cell transcriptome
  898. Abstract# 4762: The mTORC2 complex regulates C2C12 myoblast fusion through a ROCK-1-dependent pathway
  899. … MAMMALIAN TARGET OF RAPAMYCIN SIGNALING COMPLEX-2 (mTORC2): ROLE OF SUPEROXIDE ANION IN ACTIVATION OF mTORC2 IN BREAST CANCER …
  900. Abstract A16: Suppressor of morphogenesis in genitalia 1 (SMG1) is a novel negative regulator of mammalian target of rapamycin complex 2 (mTORC2)
  901. 141 PI3K REGULATES P27 THROUGH mTORC2 IN RENAL CELL CARCINOMA
  902. The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma.
  903. Abstract# SY27-1: Discovery and development of small molecule inhibitors of mTORC1 and mTORC2 as potential anti-cancer agents
  904. 475-P: Renal Loss of mTORC2 Is Associated with Improved Diabetic Nephropathy in Type 1 Diabetes
  905. MicroRNA-101 as a potential regulator of mTORC2 and HIF-2a in renal cell carcinoma
  906. … IN HUMAN RENAL CELL CARCINOMA ACHN CELLS IS MEDIATED BY CONSTITUTIVE ACTIVATION OF SIGNAL TRANSDUCTION PATHWAYS VIA mTORC2
  907. Rictor Oxidation and Disruption of the Mammalian Target of Rapamycin Complex 2 (mTORC2) Links Mitochondrial Oxidative Stress to Insulin Resistance in …
  908. The Role of Sin 1-mTORC2 in the Regulation of T Cell Homeostasis
  909. IKBKE activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 to sustain malignant transformation
  910. Calpain-2 Activates Akt via the TGF~ 1-mTORC2 Pathway in Pulmonary Artery Smooth Muscle Cells
  911. … THE TUBULAR RENIN-ANGIOTENSIN SYSTEM AND PREVENTION BY ANGIOTENSIN II RECEPTOR BLOCKADE13 mTORC2 REGULATES ENDOTHELIAL CELL …
  912. Abstract# 444: Molecular and clinical characterization of RICTOR (mTORC2) as a candidate oncogene in hepatocellular carcinoma

Related Posts

Shopping Cart
Scroll to Top